"Trump Should Put High Rx Drug Costs On Table At Trade Talks, Mount Sinai CEO Says" - Leo Vartorella
President Donald Trump's administration should address prescription drug prices in international trade negotiations, Kenneth L. Davis, MD, president and CEO of the Mount Sinai Health System, told CNBC. Dr. Davis argues it is unfair that Americans pay high prices for prescription drugs while foreign governments subsidize costs for their consumers to receive the same drugs for significantly less. "Americans wind up paying much more for our drugs than anywhere else in the world. The rest of the world controls their prices; the U.S., it's a free market,” he said. "Essentially the U.S. is underwriting the research and development costs that happen for the rest of the world. This is a trade issue. This is a fair trade issue, and we have to bring it up in trade negotiations." Dr. Davis said President Trump should encourage drug companies to raise international prices on drugs, though he added that it’s not guaranteed that those companies would pass the savings along to U.S. consumers.
- Kenneth L. Davis, MD, President, CEO, Mount Sinai Health System

Mount Sinai Health System Brings Bold Ideas in AI and Healthspan Science to Aspen 2025
Jun 18, 2025 View All Press Releases
Mount Sinai Reports Progress on Its Road Map for Action to Address Racism
Jun 07, 2023 View All Press Releases
New York’s Mount Sinai Health System Opens Concierge Medicine Practice in West Palm Beach
May 15, 2023 View All Press Releases
Deepak L. Bhatt, MD, MPH, Named Director of Mount Sinai Heart
Oct 31, 2022 View All Press Releases
Valentin Fuster, MD, PhD, Named President of Mount Sinai Heart
Oct 18, 2022 View All Press Releases